Critics say Aduhelm approval was rushed
(Newser) -
Aduhelm, the Alzheimer’s drug approved this summer in a process that led some FDA advisers to quit , is the subject of new controversy. A 75-year-old woman in Canada participating in a clinical trial died in September after going to the hospital for a seizure, the New York Times reports....